普伐他汀杂质A | 250737-12-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: 普伐他汀杂质A
• 英文名称: 6'-Epipravastatin
• 英文别名: (3R,5R)-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
• CAS: 250737-12-3
• 化学式: C₂₃H₃₆O₇
• 分子量: 424.5
• InChiKey: TUZYXOIXSAXUGO-PZSHMICQSA-N

物化性质

• 沸点：
  634.5±55.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Process for obtaining HMG-CoA reductase inhibitors of high purity
  申请人：Grahek Rok

  公开号：US20070032549A1

  公开（公告）日：2007-02-08

  Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables one to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.
• Huvastatin and its preparation and formulation comprising the huvastatin
  申请人：Ye Hongping

  公开号：US20070185193A1

  公开（公告）日：2007-08-09

  The invention relates to statin compounds, and it discloses novel small molecule compounds, i.e., huvastatins, which are classified into I, II, and III. The invention also provides the preparation methods thereof and the formulations comprising the huvastatin as active ingredient. The present compounds can be used at lower dosage compared to the existing statin compounds, and also can help to control the desired blood lipid levels of the patients with hyperlipidemia. Huvastatin of the invention exhibits suitable hydrophilicity, strong potency and therapeutical effect for reducing lipid levels, and lower dosage.
• TREATING CANCER WITH STATINS AND COMPOUNDS HAVING DIPYRIDAMOLE ACTIVITY
  申请人：Penn Linda

  公开号：US20130131088A1

  公开（公告）日：2013-05-23

  The disclosure pertains to methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a statin in combination with an effective amount of a dipyridamole and/or a compound that has dipyridamole activity.